Avanos Medical and American Industrial Partners Achieve Key Regulatory Milestone Ahead of Merger
In a recent announcement, Avanos Medical, Inc., a medical technology firm, and American Industrial Partners, an investment firm, have shared exciting news regarding their planned merger. They have successfully obtained all the necessary regulatory approvals to proceed with the acquisition of Avanos by affiliates of investment funds managed by AIP (American Industrial Partners). This marks a pivotal moment in their joint venture, indicating that both organizations are keen to move forward with their strategic plans.
The merger is set to conclude by July 27, 2026, pending the approval from Avanos stockholders and the satisfaction of customary closing conditions. To facilitate this, Avanos has scheduled a special meeting for stockholders on July 22, 2026, at 9:00 AM Eastern Time at the offices of Alston Bird LLP in Atlanta, Georgia. During this critical meeting, stockholders will review and vote on the proposed transaction, making it an essential date on the calendar.
David C. Pacitti, the CEO of Avanos, expressed enthusiasm about achieving this milestone, emphasizing the importance of collaboration between the two companies in securing the required approvals. He stated, "This achievement brings us closer to completing the transaction and embarking on a new phase of innovation and growth at Avanos." His comments highlight the positive outlook that the merger brings to both organizations, focusing on future developments in the healthcare sector.
Joel Rotroff, a partner at American Industrial Partners, echoed this sentiment, calling the regulatory approval a significant step towards achieving the merger. Rotroff expressed excitement about collaborating closely with Avanos’s leadership, emphasizing their commitment to supporting the company's growth, innovation, and commercial efforts. The partnership aims to leverage Avanos’s expertise in clinical solutions to enhance the delivery of medical device solutions that are vital for patient recovery and healthcare.
Avanos Medical, headquartered in Alpharetta, Georgia, focuses on providing superior medical device solutions designed to address critical healthcare needs. Their mission includes solutions ranging from nutritional support for patients transitioning from hospitals to home care, alongside efforts to minimize opioid usage and enhance surgical recovery pathways. Avanos has successfully developed, manufactured, and marketed well-known brands globally, holding strong market positions in various categories such as wound care and pain management.
On the other hand, American Industrial Partners operates as an investor focused on industrial firms, managing around $17.8 billion in assets. Their strategy revolves around backing companies with robust management teams and working collaboratively to implement transformative operating agendas. With a strong history of over 145 acquisitions, AIP’s expertise in optimizing business operations positions them as a strategic partner for Avanos.
As the merger gears up for completion, both companies underscore the significance of maintaining transparency and open communication with their stakeholders. Avanos has filed pertinent documents, including a definitive proxy statement, with the Securities and Exchange Commission (SEC) to facilitate the stockholder vote and provide detailed insights into the merger process. They encourage investors to review these materials thoroughly to stay informed about the impending changes.
The merger promises to create synergies that enhance efficiency and drive innovation within Avanos. As the healthcare landscape evolves, the collaboration between Avanos and AIP is expected to yield advancements that cater to modern healthcare challenges, positioning the newly formed company at the forefront of medical device solutions.
In conclusion, the successful acquisition of regulatory approvals is a crucial step for Avanos Medical and American Industrial Partners. Both organizations are poised to move forward towards a partnership that aims to innovate and enhance patient care through effective medical solutions. The upcoming stockholder meeting will serve as a stepping stone towards finalizing the merger and commencing a new chapter in their combined pursuit of excellence in the healthcare sector.
The merger is set to conclude by July 27, 2026, pending the approval from Avanos stockholders and the satisfaction of customary closing conditions. To facilitate this, Avanos has scheduled a special meeting for stockholders on July 22, 2026, at 9:00 AM Eastern Time at the offices of Alston Bird LLP in Atlanta, Georgia. During this critical meeting, stockholders will review and vote on the proposed transaction, making it an essential date on the calendar.
David C. Pacitti, the CEO of Avanos, expressed enthusiasm about achieving this milestone, emphasizing the importance of collaboration between the two companies in securing the required approvals. He stated, "This achievement brings us closer to completing the transaction and embarking on a new phase of innovation and growth at Avanos." His comments highlight the positive outlook that the merger brings to both organizations, focusing on future developments in the healthcare sector.
Joel Rotroff, a partner at American Industrial Partners, echoed this sentiment, calling the regulatory approval a significant step towards achieving the merger. Rotroff expressed excitement about collaborating closely with Avanos’s leadership, emphasizing their commitment to supporting the company's growth, innovation, and commercial efforts. The partnership aims to leverage Avanos’s expertise in clinical solutions to enhance the delivery of medical device solutions that are vital for patient recovery and healthcare.
Avanos Medical, headquartered in Alpharetta, Georgia, focuses on providing superior medical device solutions designed to address critical healthcare needs. Their mission includes solutions ranging from nutritional support for patients transitioning from hospitals to home care, alongside efforts to minimize opioid usage and enhance surgical recovery pathways. Avanos has successfully developed, manufactured, and marketed well-known brands globally, holding strong market positions in various categories such as wound care and pain management.
On the other hand, American Industrial Partners operates as an investor focused on industrial firms, managing around $17.8 billion in assets. Their strategy revolves around backing companies with robust management teams and working collaboratively to implement transformative operating agendas. With a strong history of over 145 acquisitions, AIP’s expertise in optimizing business operations positions them as a strategic partner for Avanos.
As the merger gears up for completion, both companies underscore the significance of maintaining transparency and open communication with their stakeholders. Avanos has filed pertinent documents, including a definitive proxy statement, with the Securities and Exchange Commission (SEC) to facilitate the stockholder vote and provide detailed insights into the merger process. They encourage investors to review these materials thoroughly to stay informed about the impending changes.
The merger promises to create synergies that enhance efficiency and drive innovation within Avanos. As the healthcare landscape evolves, the collaboration between Avanos and AIP is expected to yield advancements that cater to modern healthcare challenges, positioning the newly formed company at the forefront of medical device solutions.
In conclusion, the successful acquisition of regulatory approvals is a crucial step for Avanos Medical and American Industrial Partners. Both organizations are poised to move forward towards a partnership that aims to innovate and enhance patient care through effective medical solutions. The upcoming stockholder meeting will serve as a stepping stone towards finalizing the merger and commencing a new chapter in their combined pursuit of excellence in the healthcare sector.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.